Biogen Idec Inc. announced on October 9th that it was discontinuing development of its investigational rheumatoid arthritis (RA) drug baminercept after if failed to meet Phase II study endpoints. [...]
|
|||||||
 |
  
|
||||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments